NasdaqGS:PRAXBiotechs
Is Widening Losses And The Pivotal POWER1 Readout Altering The Investment Case For Praxis (PRAX)?
Praxis Precision Medicines recently reported first-quarter 2026 results showing a wider net loss of US$92.56 million year over year, while its leadership team continued plan-based share purchases through the Employee Stock Purchase Plan and presented at the Bank of America Global Healthcare Conference in Las Vegas.
Together with cautious sentiment ahead of the pivotal POWER1 Phase 3 epilepsy trial readout, these developments have sharpened investor focus on Praxis’s cash burn and clinical...